title: Comment on 'Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab'.
authors: H
authors: H
authors: Shimokawa
authors: H
authors: H
authors: Uramoto
authors: F
authors: F
authors: Tanaka
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy*; D008297:Male
chemical_list: D007334:Insulin-Like Growth Factor I